JP6632677B2 - Antimicrobial coating and method for forming same - Google Patents

Description

FIELD OF THE INVENTION Embodiments generally relate to anti-microbial coating compositions and methods of using the coating compositions. In certain embodiments, the coating composition contains a photocatalyst. In certain embodiments, the photocatalyst includes a titanyl-oxide moiety. In certain embodiments, the coating composition contains a silane.

The invention will be better understood by reading the following detailed description in conjunction with the drawings. In the drawings, the same reference symbols are used to represent the same elements.

FIG. 1 graphically shows the number of hospital-acquired C-difficile infections at Glendale Memorial Hospital ICU from January 2012 to February 2014.

FIG. 2 graphically shows the number of hospital-acquired C-difficile infections at Glendale Memorial Hospital (other than ICU) from January 2012 to February 2014.

FIG. 3 shows antimicrobial efficacy data at 0 hours after inoculation of the treated test coupon.

FIG. 4 shows antimicrobial efficacy data 4 hours after inoculation of the treated test strips, including data for ABS-G2020 and ABS-G2030-treated formica strips.

FIG. 5 shows antimicrobial efficacy data 4 hours after inoculation of the treated test specimens, including data for stainless steel coupons treated with ABS-G2020 and ABS-G2030.

FIG. 6 shows a surface time-kill study evaluating two coating formulations for mouse norovirus, data for a contact time of 6 hours.

FIG. 7 shows CFU / mL data for each of the three coating formulations, where each formulation did not contain one or more titanium oxide moieties.

FIG. 8 shows Log reduction data for the three formulations evaluated, where each formulation did not include one or more titanium oxide moieties.

FIG. 9 shows the percent reduction data for the three formulations utilized, where each formulation did not contain one or more titanium oxide moieties.

FIG. 10 shows antimicrobial efficacy data for certain electrostatic spray embodiments.

FIG. 11 shows antimicrobial efficacy data for certain electrostatic spray embodiments.

FIG. 12 shows antimicrobial efficacy data for certain electrostatic spray embodiments.

FIG. 13 shows antimicrobial efficacy data for certain non-electrostatic spray embodiments.

FIG. 14 shows antimicrobial efficacy data for certain non-electrostatic spray embodiments.

FIG. 15 shows antimicrobial efficacy data for certain non-electrostatic spray embodiments.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention is described in the following description with reference to the figures. In the figures, the same numbers represent the same or similar elements. Reference to “an embodiment,” “an embodiment,” or similar language throughout this specification may refer to a particular feature, structure, or characteristic described in connection with that embodiment. It is meant to be included in the embodiment. Thus, appearances of the phrases "in one embodiment", "in one embodiment", and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment. Good.

The described features, structures, or characteristics of the invention may be combined in any suitable manner in one or more embodiments. In the following description, numerous specific details are set forth in order to provide a thorough understanding of embodiments of the present invention. However, those skilled in the art will recognize that the invention may be practiced without one or more of the specific details, or may be practiced using other methods, components, materials and the like. Recognize that it may be good. In other instances, well-known structures, materials, or operations are not shown or described in detail to avoid obscuring aspects of the present invention.

In certain embodiments of our compositions and methods, a coating is formed on a surface, where the coating comprises a plurality of silicon-oxygen bonds. In certain embodiments of our compositions and methods, a coating is formed on a surface, where the coating comprises a plurality of titanium-oxygen bonds in combination with a plurality of silicon-oxygen bonds.

In certain embodiments, the coating comprising a plurality of titanyl-oxide linkages in combination with a plurality of silicon-oxygen linkages comprises a silane on the surface comprising one or more titanyl-oxygen linkages. Formed by placing in combination with one or more compounds, including: In certain embodiments, a coating comprising a plurality of titanyl-oxide bonds in combination with a plurality of silicon-oxygen bonds initially comprises one or more titanyl-oxide bonds comprising one or more titanyl-oxygen bonds. The compound is placed on the surface and the silane is deposited on the surface with the one or more titanyl-
It is formed by placing over one or more compounds containing oxygen bonds. In certain embodiments, a coating comprising a plurality of titanyl-oxide bonds in combination with a plurality of silicon-oxygen bonds, comprises one or more compounds comprising one or more titanyl-oxygen bonds, The silane is formed by placing the silane on this surface simultaneously.

を含む。 In certain embodiments, our silane is Compound 1

including.

In certain embodiments, R1 is selected from the group consisting of OH and O-alkyl. In certain embodiments, R2 is selected from the group consisting of OH and O-alkyl. In certain embodiments, R3 is selected from the group consisting of OH and O-alkyl. In certain embodiments, R4 is selected from the group consisting of OH, O-alkyl, alkyl, substituted alkyl (including γ-chloro-propyl, γ-amino-propyl, and quaternary ammonium salt substituted alkyl). You.

を含む。 In certain embodiments, our silane is trihydroxysilane 2

including.

In certain embodiments, our silane comprises silanetriol 2 , wherein R4 is alkyl. In another embodiment, our silane comprises silanetriol 2 , wherein R4 is alkyl having an amino moiety. In yet other embodiments, our silane comprises silanetriol 2 , wherein R4 is alkyl having a chlorine substituent. In yet another embodiment, our silane comprises silanetriol 2 , wherein R4 is alkyl having a quaternary ammonium group.

特定の実施形態において、本発明者らのシラン1または2を、硬い表面（すなわち、壁、
扉、およびテーブルなど）、または軟らかい表面（すなわち、寝具、生地（drapery）、
および家具のクッションなど）のいずれかに付与した後に、この硬い表面/軟らかい表面
上に配置された、得られるコーティングは、複数のシルセスキオキサン構造を含む。特定
の実施形態において、本発明者らのシラン1または2を、チタニル-酸素部分を含む１つま
たはそれより多くの化合物と組み合わせて、硬い表面（すなわち、壁、扉、およびテーブ
ルなど）、または軟らかい表面（すなわち、寝具、生地、および家具のクッションなど）
のいずれかに付与した後に、この硬い表面/軟らかい表面の上に配置された、得られるコ
ーティングは、複数のシルセスキオキサン構造3を、複数のチタニル-オキシド構造と組み
合わせて含む。 Silsesquioxane is an organosilicon compound 3 , where S
i represents the elemental silicon and O represents the elemental oxygen.

In certain embodiments, our silane 1 or 2 is applied to a hard surface (ie, a wall,
Doors and tables, etc.) or soft surfaces (ie bedding, draperies)
And after being applied to any of the furniture cushions), the resulting coating disposed on this hard / soft surface contains multiple silsesquioxane structures. In certain embodiments, our silane 1 or 2 is combined with one or more compounds containing a titanyl-oxygen moiety to provide a hard surface (ie, walls, doors, tables, etc.), or Soft surfaces (ie, bedding, fabric, and furniture cushions, etc.)
After being applied to any of the above, the resulting coating disposed on this hard / soft surface comprises a plurality of silsesquioxane structures 3 in combination with a plurality of titanyl-oxide structures.

Oxidation is the loss of electrons or an increase in the oxidation state by a molecule, atom or ion.
Substances that have the ability to oxidize other substances are said to be oxidative or oxidizing, and oxidizing agents, oxidants
dant), or oxidizer. In other words, the oxidant removes electrons from another substance and is therefore reduced itself. And this is the electron "
Because it accepts, it is also called an electron acceptor.

In chemistry, photocatalysis is the acceleration of a photoreaction in the presence of a catalyst. In catalyzed photolysis, light is absorbed by the adsorbed substrate. In light-induced catalysis, photocatalytic activity (PCA) depends on the ability of the catalyst to generate electron-hole pairs, which convert free radicals (hydroxyl radicals: OH) that can undergo secondary reactions. Generate. That understanding has been made possible since the discovery of the electrolysis of water by titanium dioxide.

Certain forms of titanyl-oxide exhibit photocatalytic properties when exposed to ultraviolet (UV) light. When exposed to UV light, our titanyl-oxide moieties generate electron-hole pairs, which generate free radicals (eg, hydroxyl radicals). The degree of photocatalytic intensity varies depending on the type of titanyl-oxide, for example, anatase titanium oxide (particle size of about 5-30 nanometers) is rutile titanium oxide (particles of about 0.5-1 micron). It is a stronger photocatalyst.

In certain embodiments of our compositions and methods, a coating is formed on a surface, wherein the coating comprises a plurality of titanyl-oxide bonds, wherein the coating comprises a layer of our coating. Formed by placing a titanyl-oxide moiety on the target surface.

In certain embodiments of our compositions and methods, a coating is formed on a surface, wherein the coating comprises a plurality of silicon-oxygen bonds, wherein the coating comprises a layer of our coating. It is formed by placing silane 1 on this surface.

In certain embodiments of our compositions and methods, a coating is formed on a surface, wherein the coating comprises a plurality of titanyl-oxide bonds, wherein the coating comprises: Peroxotitanic acid solution and peroxo-modified anatase (
modified anatase) formed by placing a mixture with the sol (collectively, the "titanyl-oxide moiety").

In certain embodiments, our titanyl-oxide moiety comprises a loading of a mixture of a peroxotitanic acid solution and a peroxo-modified anatase sol, up to a total of about 1 weight percent. In certain embodiments, our titanyl-oxide moiety comprises about 0.5 weight percent peroxotitanic acid solution in combination with about 0.5 weight percent peroxo-modified anatase sol.

A method for preparing both a peroxotitanic acid solution and a peroxo-modified anatase sol comprises:
Journal of Sol-Gel Science and Technology, September 2001, Volume 22,
Issue 1-2, pp 33-40. This publication discloses, among other things, Reaction Scheme 1 set forth immediately below, which summarizes the synthetic procedures for both peroxotitanic acid solutions and peroxo-modified anatase sols.
Reaction Scheme 1

を有する、シリコーン（silicone）含有化合物を含有する。 In the following examples, reference is made to the coatings ABS-G2015, ABS-G2020 and ABS-G2030. The coating formulation ABS-G2015 has a structure V :

A silicone-containing compound having the formula:

The coating formulation ABS-G2015 further comprises a titanyl-oxide moiety. The order of the deposition on the surface is not important. In certain embodiments, the silicone-containing compound is first disposed on a surface, and the titanyl-oxide moiety is disposed over the silicone-containing compound. In other embodiments, the titanyl-oxide moiety is first disposed on a surface, and the silicone-containing compound is
It is placed over the surface treated with the oxide moiety. In still other embodiments, the titanyl-oxide moiety and the silicone-containing compound are first premixed, and the resulting mixture is disposed on the surface of a substrate.

を有する、シリコーン含有化合物を含有する。 The coating formulation ABS-G2020 has the structure VI :

And containing a silicone-containing compound.

The coating formulation ABS-G2020 further comprises a titanyl-oxide moiety. The order of deposition on the surface is not important. In certain embodiments, the silicone-containing compound is first disposed on a surface, and the titanyl-oxide moiety is disposed over the silicone-containing compound. In other embodiments, the titanyl-oxide moiety is first disposed on a surface, and the silicone-containing compound is disposed over the surface treated with the titanyl-oxide moiety. In still other embodiments, the titanyl-oxide moiety and the silicone-containing compound are first pre-mixed and the resulting mixture is
It is located on the surface of the substrate.

を有する、シリコーン含有化合物を含有する。 The coating formulation ABS-G2030 has structure VII :

And containing a silicone-containing compound.

The coating formulation ABS-G2030 further comprises a titanyl-oxide moiety. The order of deposition on the surface is not important. In certain embodiments, the silicone-containing compound is first disposed on a surface, and the titanyl-oxide moiety is disposed over the silicone-containing compound. In other embodiments, the titanyl-oxide moiety is first disposed on a surface, and the silicone-containing compound is disposed over the surface treated with the titanyl-oxide moiety. In still other embodiments, the titanyl-oxide moiety and the silicone-containing compound are first pre-mixed and the resulting mixture is
It is located on the surface of the substrate.

The following examples are provided to those skilled in the art to further illustrate how to make and use the present invention. These examples are not intended in any way to be a limitation on the scope of the invention.

Example 1
Example 1 This example evaluates the antimicrobial efficacy of coatings ABS-G2015, ABS-G020, and ABS G-2030 against murine norovirus. Mouse norovirus (MNV) is a species of norovirus that infects mice. Norovirus is the most common cause of viral gastroenteritis in humans. It infects humans of all ages. The virus is transmitted, inter alia, by aerosolization of the virus and subsequent contamination of the surface. The virus affects approximately 267 million people each year and causes over 200,000 deaths. These deaths are usually in less developed countries, and in very young, elderly, and immunosuppressed humans.

The test strip of this Example 1 was prepared using the procedure described immediately below.

Procedure Wear sterile gloves.

Specimens are prepared by first wiping with isopropyl alcohol and drying.

The specimens are cleaned using a microfiber cloth with a surface cleaner.

  The sprayer is held about 8 inches from the surface to be cleaned.

Spray and leave it for 1-3 minutes, then wipe it off. If the area is extremely dirty, run the cleaner for a longer time or do a second spray and wipe.

  Wipe the surface with a clean damp sponge or cloth.

  Allow the surface to dry completely.

  With a gloved hand, examine the piece for consistency.

A 10 volume percent solution of the selected silane in methanol (MeOH) (10 ml
silane).

  Triethanolamine is prepared as a 10 volume percent solution in MeOH.

Combine the triethanolamine solution and the silane solution in a 1: 1 ratio on a stir plate at room temperature (ie, add 100 ml of the triethanolamine solution to 100 ml of the silane solution).

Applying silane
Add the silane / triethanolamine solution from [0041] to the applicator container.

  Secure the liquid hose / bottle cap assembly to the container.

  Connect the air hose from the compressor to the air fitting on the spray applicator.

  Connect the fluid hose to the spray applicator fluid fitting.

  Plug the power cord into a suitable outlet. Turn on the air compressor.

  The optimal spray distance is at least 36 to 48 inches away from the target surface.

  Hold the spray gun at right angles to the target surface and spray.

The target surface should be barely glowing with this spray. Do not oversaturate this surface.

Dry the target surface. That is, at least 90 weight percent of the methanol liquid carrier is evaporated to obtain a film consisting essentially of the selected silane and triethanolamine. The deposition on the target surface consists of at least 33 volume percent of the selected silane, at least 33 volume percent of triethanolamine, and up to about 33 volume percent of the residual methanol carrier liquid.

Rinse the spray gun with distilled water and then apply our titanyl-oxide moiety (unless two atomizers, one for each product, each).

Addition of a titanyl-oxide moiety.
An aqueous mixture of our titanyl-oxide moiety is added to an applicator container.

  Secure the liquid hose / bottle cap assembly to the container.

  Connect the air hose from the compressor to the air fitting on the spray applicator.

  Connect the fluid hose to the spray applicator fluid fitting.

  Plug the power cord into a suitable outlet. Turn on the air compressor.

  The optimal spray distance is at least 36 to 48 inches away from the target surface.

  Hold the spray gun at right angles to the target surface and spray.

The target surface should be barely glowing with this spray. Do not oversaturate this surface.

Dry the target surface. That is, at least 90 weight percent of the aqueous liquid carrier is evaporated to yield a film consisting essentially of our titanyl-oxide moiety. The deposition on this target surface is at least 66 volume percent of our titanyl-oxide moiety,
And up to about 33 volume percent residual water carrier liquid.

  After each use day, clean the spray gun with distilled water according to the manufacturer's specifications.

Figures 4 and 5 show antimicrobial efficacy data 4 hours after inoculation of the treated test strips. Figure 4
Contains data on formica pieces treated with ABS-G2020 and ABS-G2030. Figure
5 contains data for stainless steel pieces treated with ABS-G2020 and ABS G-2030.

RAW (mouse macrophage) host cells are used in the test in a 96-well tray 2
Prepared 4 hours ago.

On the test day, a stock vial of the test virus, mouse norovirus, was removed from storage at -80 ° C (titer = 5 × 10 ⁸ TCID 50 units per ml). Organic Pollutant Road (organ
An ic soil load (heat-inactivated fetal calf serum) was added to obtain a final concentration of 5%.

Controls (uncoated stainless steel and formica) and coated test carriers [ABS-G2015 (SS); ABS-G2020 (Form); ABS-G2030 (Form); ABS-P
2015 (SS)] were placed in sterile Petri dishes (one per dish) using pre-sterilized forceps.

The virus inoculum (0.010 ml) was pipetted into the center of the control and test carriers and spread over a surface area of about 1 in ² using a sterile bent pipette tip.

Immediately collect / neutralize one set of control carriers (per type of surface material), 3m
Time zero counts were determined by placing into a sterile stomacher bag containing 1 l of neutralizing solution (calf calf supplemented with 0.001% Na thiosulfate and 0.001% Na thioglycolate). These bags were stomached at high speed for 120 seconds to release these viruses from the carrier.

The remaining control and test carriers were held under ambient conditions for each of the specified study contact times of 4 hours and 24 hours [Placement distance / configuration: about 68 inches of two full spectrum bulbs ( 1.7m) downward, inoculated surface facing upwards to light)] All carriers were observed to be dry within 10 minutes of inoculation.

At the end of each contact time, the control carrier and test carrier were neutralized by placing them in a sterile stomacher bag containing 3 ml of neutralizing solution, as described above, followed by a stomach treatment.

At the beginning and end of each contact time, room temperature, relative humidity, and lux were measured and recorded.

The control carrier and test carrier eluates were serially diluted (1:10) and
And plated on RAW host cells prepared at the appropriate confluency.

Observe these plates every 24-48 hours to determine the cytopathic effect (CPE) of the virus.
And cytotoxicity was visualized.

After a 9-day assay incubation period, the plates were scored formally.

Log10 reductions and percent reductions were calculated for the timed control virus counts (per surface type) for each of the test coating formulations. However, 2
For a contact time of 4 hours, no reduction could be calculated due to insufficient virus recovery from the control carrier.

Check the neutralization for each of the test coating formulations (ABS-P20
(Except 15) One control carrier and one of each test carrier type were placed in a stomacher bag containing 3 ml of neutralizing agent and processed as described above. The eluate was serially diluted and a low titer inoculum of the test virus (about 3 log 1
0) was added to each of the dilution tubes for each suspension of control carrier and test carrier. Aliquots (0.1 ml) of these suspensions were then plated in order to assess the level of cytotoxicity of the neutralized test material.

Example 2
This Example 2 demonstrates the coating formulations, namely, ABS-G2015, ABS-G2020, and ABS-G
The three silanes utilized in 2030 are utilized, but without any titanyl-oxide containing compounds. The method of paragraphs [0044] to [0064] of Example 1 relating to spray film formation on a test piece of silane was used in Example 2. The methods of paragraphs [0065] to [0074] (including these paragraphs) for spray deposition of the titanyl-oxide moiety were not utilized in this Example 2.

FIG. 7 shows CFU / mL data for each of the three coating formulations, where each formulation did not include one or more titanium oxide moieties. FIG. 8 shows Log reduction data for the three formulations evaluated, where each formulation did not contain one or more titanium oxide moieties. FIG. 9 shows the percent reduction data for the three formulations utilized, where each formulation did not include one or more titanium oxide moieties.

Example 3
This Example 3 utilizes the complete formulations ABS-G2015, AB-G2020, and ABS-G2030. Here, these coating formulations were placed on stainless steel coupons using the entire procedure of Example 1. In one set of experiments, these formulations were placed on test specimens using an electrostatic spray assembly. In another set of experiments, these formulations were placed on test specimens using a non-electrostatic spray assembly.

FIGS. 10, 11, and 12 show antimicrobial efficacy data for the electrostatic spray embodiment. FIGS. 13, 14, and 15 show antimicrobial efficacy data for non-electrostatic spray embodiments.

Example 4
Research was conducted at Glendale, CA's Glendale Memorial Hospital and Health Center
("Glendale Memorial Hospital Study"). The center has a 24-bed intensive care unit (ICU)
There is. The study was conducted from May 10 to September 30, 2013. Glendale Memorial
Hospital studies were designed to evaluate the antimicrobial efficacy of the coating composition ABS-G2015 described hereinabove, where the coating composition was prepared according to the complete method of Example 1 herein. Granted using.

In the Glendale Memorial Hospital study, the entire ICU was
Provide all surfaces (including hard surfaces (beds, tray tables, bed railings, walls, etc.) and soft surfaces (such as chairs covered with fabric, cloth and vinyl)) to the stage spray regimen Processed. More specifically, an aqueous composition formed on each surface by first mixing octadecylaminodimethyltrihydroxysilylpropylammonium chloride ("silylated quaternary amine") at room temperature at about 3.6 weight percent in water Was used to coat with electrostatic spray.

About 15 minutes after electrostatic spray coating using this aqueous silylated quaternary amine,
Each surface was electrostatically coated at room temperature using the titanyl-oxide moiety described herein above.

The treated surface was maintained at room temperature during spray deposition of the aqueous silylated quaternary amine and during spray deposition of the titanyl-oxide moiety. None of the treated surfaces was subjected to high temperature heat treatment. In this heat treatment, the treated surface was heated to approximately above room temperature after completion of the two-step coating regimen.

Ninety-five specific locations within the ICU were selected to repeat sampling at week 1, week 2, week 4, week 8, and week 15 after the two-step spray regimen. These selected locations are
Included bed railings, bed controls, tray tables, and walls above the sink. Samples were also collected from two ICU nursing stations and a waiting lobby, including a countertop, telephone, computer keyboard, armchair and end table. All movable articles were inconspicuously tagged and marked during the course of this study so that the same object could be sampled.

An area of 100 cm ^2, Rezen broth to neutralize any residual disinfectant (3M, St.Paul, MN
) Was sampled using a sponge stick containing After collection, these samples were immediately placed on ice sacs and overnight, for analysis by Professor Charles Gerba, Universi
Sent to ty of Arizona.

FIG. 1 herein shows Dignity Health / Glendale Memorial Hospital & Health Cent
A legitimate and exact copy of the first graph provided by er Infection Prevention Manager. Evidence 1 graphically illustrates the number of hospital-acquired C-difficile infections at Glendale Memorial Hospital ICU from January 2012 to February 2014.

FIG. 1 shows that no hospital-acquired C-difficile infection occurred in the ICU during the period from May 2013 to November 2013, except for September 2013. Thus, FIG. 1 shows that a single nosocomically infected C-diffy occurred in the ICU during the six months from May 2013 to November 2013.
Indicates that cile infection was present.

Figure 1 also shows that, apart from the six-month period from May 2013 to November 2013,
This indicates that there was no other 6-month period during which nosocomial C-difficile infection occurred once in the ICU during the 25 months to February 4 years.

All surfaces in the ICU were treated during the first week of May 2013, as described herein above, as part of the Glendale Memorial Hospital study. FIG. 2 of this specification
Here is a legitimate and exact copy of the second graph provided by the Manager of Infection Prevention at Health / Glendale Memorial Hospital & Health Center. Evidence 2 graphically shows the number of hospital-acquired C-difficile infections at Glendale Memorial Hospital (other than ICU) from January 2012 to February 2014.

FIG. 2 shows that, except for April 2013, there were 1 to 8 nosocomial C-difficile infections each month during the 25-month period outside the ICU, in the hospital area. During the period from May 2013 to November 2013, FIG. 2 shows that there were a total of 20 hospital-acquired C-difficile infections that occurred outside the ICU at Glendale Memorial Hospital.

FIGS. 1 and 2 show one hospital-acquired C-diffic during the period from May 2013 to November 2013.
Figure 7 shows that ile infection occurred in the Glendale Memorial Hospital ICU and that a total of 20 hospital-acquired C-difficile infections occurred outside the Glendale Memorial Hospital ICU.

Clostridium difficile colitis or pseudomembranous enteritis is colitis (inflammation of the large intestine) resulting from infection with Clostridium difficile (a type of spore-forming bacterium). This causes an infectious diarrhea called C. difficile diarrhea. The latent symptoms of Clostridium difficile infection (CDI) often mimic some influenza-like symptoms and can mimic disease recurrence in humans with colitis associated with inflammatory bowel disease. C. difficile releases toxins that can cause bloating and diarrhea with abdominal pain, which can be severe.

C. difficile is transmitted from person to person by the fecal-oral route. This creature
Alcohol-based hand cleanser and conventional surface cleaning do not kill,
Form heat resistant spores. Thus, these spores survive in the clinical setting for long periods of time. Due to this, the bacteria can be cultured from almost any surface.

Clostridium difficile spores are extremely robust and can survive for long periods in food-free environments. These spores are resistant to drying and heating, and also resistant to many forms of preservative cleaners. C. diff can also survive as long as 5 months in the form of spores. The ability of C.diff. To survive in this resistant form creates a great challenge for hospitals.

The data in Figures 1 and 2 are based on Glendale Memo, since C.diff forms heat-resistant spores that are not killed by alcohol-based hand cleansers or conventional surface cleaning.
It demonstrates that treatment of hard and soft surfaces in the rial Hospital ICU with ABS-G2015 necessarily reduced the occurrence of C. diff spores in this ICU. The data in FIG. 2 show that other departments of the hospital, which were not treated with the ABS-G2015 coating composition, experienced much higher levels of hospital-acquired C. diff infection, which indicated that Confirm the antimicrobial efficacy of the coating obtained from the application on the spores of C.diff.

In the coating formulations ABS G2015, G2020, and G2030, depending on the stoichiometry of the mixture of triethanolamine and organosilane, one or a polymer species is formed on the treated surface. In certain embodiments, as shown in Reaction Scheme 2,
The triethanolamine 9 reacts with the organosilane 1 to form a linear polymer 10, where n is greater than or equal to 1 and less than or equal to about 10.
Reaction Scheme 2

ここで反応スキーム3において、xは、1より大きいかまたは1に等しく、かつ約10より小
さいかまたは約10に等しく、そしてyは、1より大きいかまたは1に等しく、かつ約10より
小さいかまたは約10に等しい。 In another embodiment, as shown in Scheme 3, triethanolamine 9 reacts with organosilane 1 to form a branched polymer 11.
Reaction Scheme 3

Here, in Reaction Scheme 3, x is greater than or equal to 1 and less than or equal to about 10 and y is greater than or equal to 1 and less than about 10. Or equal to about 10.

ここで反応スキーム4において、xは、1より大きいかまたは1に等しく、かつ約10より小
さいかまたは約10に等しく、そしてyは、1より大きいかまたは1に等しく、かつ約10より
小さいかまたは約10に等しく、そしてzは、1より大きいかまたは1に等しく、かつ約10よ
り小さいかまたは約10に等しい。 In another embodiment, the triethanolamine 9 reacts with the organosilane 1 to form a crosslinked polymer 12, as shown in Scheme 4.
Reaction Scheme 4

Here, in reaction scheme 4, x is greater than or equal to 1 and less than or equal to about 10 and y is greater than or equal to 1 and less than about 10. Or equal to about 10 and z is greater than or equal to 1 and less than or equal to about 10.

ここで反応スキーム5において、aは、1より大きいかまたは1に等しく、かつ約10より小
さいかまたは約10に等しく、そしてbは、1より大きいかまたは1に等しく、かつ約10より
小さいかまたは約10に等しく、そしてcは、1より大きいかまたは1に等しく、かつ約10よ
り小さいかまたは約10に等しく、そしてdは、1より大きいかまたは1に等しく、かつ約10
より小さいかまたは約10に等しい。 In certain embodiments, our organosilane comprises tetraethylorthosilicate 13. In certain embodiments, as shown in Reaction Scheme 5, starting material 9
Depending on the stoichiometry with 13, our crosslinked polymeric material 14 is formed by the reaction of tetraethylorthosilicate 13 with triethanolamine 9. Reaction scheme 5 is
1 illustrates one Si atom from which two different polymer chains extend. One skilled in the art will appreciate that our cross-linked polymeric material 14 has a very high cross-link density.
Reaction Scheme 5

Here, in Reaction Scheme 5, a is greater than or equal to 1 and less than or equal to about 10 and b is greater than or equal to 1 and less than about 10. Or equal to about 10 and c is greater than or equal to 1 and less than or equal to about 10 and d is greater than or equal to 1 and about 10
Less than or equal to about 10.

ここで反応スキーム6において、aは、1より大きいかまたは1に等しく、かつ約10より小
さいかまたは約10に等しく、そしてbは、1より大きいかまたは1に等しく、かつ約10より
小さいかまたは約10に等しく、そしてcは、1より大きいかまたは1に等しく、かつ約10よ
り小さいかまたは約10に等しく、そしてdは、1より大きいかまたは1に等しく、かつ約10
より小さいかまたは約10に等しい。 In certain embodiments, as shown in Reaction Scheme 6, depending on the stoichiometry of the starting materials 15 and 13, our crosslinked polymeric material 16 is a tetraethylorthosilicate 13
And diethanolamine 13 to form. Reaction Scheme 6 illustrates one Si atom with four different polymer chains extending. Those skilled in the art will appreciate that our cross-linked polymeric material 16 has a very high cross-link density.
Reaction Scheme 6

Here, in reaction scheme 6, a is greater than or equal to 1 and less than or equal to about 10 and b is greater than or equal to 1 and less than about 10. Or equal to about 10 and c is greater than or equal to 1 and less than or equal to about 10 and d is greater than or equal to 1 and about 10
Less than or equal to about 10.

While the preferred embodiments of the invention have been described in detail, it should be apparent that modifications and adaptations to these embodiments may occur to those skilled in the art without departing from the scope of the invention.

According to a preferred embodiment of the present invention, for example, the following is provided.
(Claim 1)
  Triethanolamine and structure:

An antimicrobial coating formulation consisting essentially of a silane having the formula:
(Claim 2)
  The surface before the deposition of the silane is placed on the surface immediately after inoculation of the mouse norovirus.
Having an initial concentration of murine norovirus isolated;
  Four hours after inoculating the surface with the mouse norovirus, the concentration of the mouse norovirus is:
About 100% lower,
Item 4. The antimicrobial coating according to item 1 above.
(Claim 3)
  Item 3. The antimicrobial coating of Item 2, wherein the surface is formed from stainless steel.
(Claim 4)
  Construction:

A silane having
  A mixture of peroxotitanic acid and peroxo-modified anatase sol;
  And triethanolamine
An antimicrobial coating formulation consisting essentially of
(Claim 5)
  Immediately after inoculation of the mouse norovirus, the surface before the formation of the antimicrobial coating
Having an initial concentration of murine norovirus disposed on the surface;
  Four hours after inoculating the surface with the mouse norovirus, the concentration of the mouse norovirus is:
About 99.5% lower,
Item 5. The antimicrobial coating composition according to the above item 4.
(Claim 6)
  The antimicrobial coating according to claim 4, wherein the surface is formed from stainless steel.
Formulation.
(Claim 7)
  Triethanolamine and structure:

An antimicrobial coating formulation consisting essentially of a silane having the formula:
(Claim 8)
  The surface prior to the formation of the first coating is immediately after the inoculation of the mouse norovirus.
Having an initial concentration of murine norovirus located at;
  Four hours after inoculating the surface with the mouse norovirus, the concentration of the mouse norovirus is:
About 100% lower,
Item 8. The antimicrobial coating formulation according to the above item 7.
(Claim 9)
  The antimicrobial coating according to claim 8, wherein the surface is formed from stainless steel.
Formulation.
(Claim 10)
  Construction:

A silane having
  A mixture of peroxotitanic acid and peroxo-modified anatase sol;
  And triethanolamine
An antimicrobial coating formulation consisting essentially of
(Claim 11)
  The surface before the formation of the antimicrobial coating is immediately
Having an initial concentration of murine norovirus disposed thereon;
  Four hours after inoculating the surface with the mouse norovirus, the concentration of the mouse norovirus is:
About 99.8% decrease,
Item 11. The antimicrobial coating composition according to the above item 10.
(Claim 12)
  The antimicrobial coating according to claim 10, wherein the surface is formed from stainless steel.
Formulation.
(Claim 13)
  A method for preparing an antimicrobial surface, comprising:
  Placing a mixture of triethanolamine and silane in a liquid carrier on the surface.
The silane has the structure:

A process comprising a compound having
  Evaporating the liquid carrier to consist essentially of the silane and triethanolamine
Forming a first coating;
  Mixing a mixture of peroxotitanic acid and peroxo-modified anatase sol in a water carrier
Placing on a surface;
  Evaporating the water carrier to form the peroxotitanic acid and peroxo-modified anatase sol;
Forming a second coating of titanyl-oxide consisting essentially of a mixture of
A method comprising:
(Claim 14)
  The silane coating is first formed on the surface;
  The titanyl-oxide coating is formed over the silane coating;
Item 14. The method according to Item 13 above.
(Clause 15)
  The titanyl-oxide coating is first formed on the surface;
  The silane coating is formed over the titanyl-oxide coating;
Item 14. The method according to Item 13 above.
(Clause 16)
  A method for preparing an antimicrobial surface, comprising:
  Silane, triethanolamine, and peroxotitanic acid in a liquid carrier
Disposing a mixture with an oxo-modified anatase sol on a surface,
The structure is:

A process consisting essentially of a compound having
  Evaporating the liquid carrier
A method comprising:
(Claim 17)
  A method for preparing an antimicrobial surface, comprising:
  Arranging silane and triethanolamine in a liquid carrier on a surface;
Thus, the silane coating has the structure:

A process consisting essentially of a compound having
  Evaporating the liquid carrier to form a coating consisting essentially of the silane.
About;
  A mixture of peroxotitanic acid and peroxo-modified anatase sol in a water carrier is
Placing on a surface;
  Evaporating the water carrier to form the peroxotitanic acid and peroxo-modified anatase sol;
Forming a titanyl-oxide coating consisting essentially of a mixture of
A method comprising:
(Claim 18)
  The silane coating is first formed on the surface;
  The titanyl-oxide coating is formed over the silane coating;
Item 18. The method according to Item 17 above.
(Claim 19)
  The titanyl-oxide is first formed on the surface;
  The silane coating is formed over the titanyl-oxide coating;
Item 18. The method according to Item 17 above.
(Claim 20)
  A method for preparing an antimicrobial surface, comprising:
  Silane, triethanolamine, and peroxotitanic acid in a liquid carrier
Disposing the mixture with the oxo-modified anatase sol on the surface, comprising:
The structure is:

A process consisting essentially of a compound having
  Evaporating the liquid carrier
A method comprising:

Claims (9)

A method of forming an antimicrobial coating on a surface, comprising:
3-chloropropyl silane triol or 3-aminopropyl silane triol, silane; and step a including placing a coating formulation containing triethanolamine on said surface,
Method.   The method of claim 1, wherein the coating formulation further comprises methanol.   The method according to claim 1, wherein the silane is 3-chloropropylsilanetriol.   4. The method of claim 3, wherein the antimicrobial coating so formed exhibits a 4.74 log reduction of murine norovirus one hour after the first inoculation of the murine norovirus on the surface.   4. The method of claim 3, wherein the antimicrobial coating so formed exhibits a 5.55 log reduction of murine norovirus 4 hours after the first inoculation of the murine norovirus on the surface.   The method of claim 1, wherein the silane is 3-aminopropylsilanetriol.   7. The method of claim 6, wherein the antimicrobial coating so formed exhibits a 7.04 log reduction of mouse norovirus one hour after the first inoculation of the mouse norovirus on the surface.   7. The method of claim 6, wherein the antimicrobial coating so formed exhibits a 6.55 log reduction in murine norovirus 4 hours after the first inoculation of the murine norovirus on the surface.   The method of claim 1, wherein the step of positioning comprises spraying the coating formulation onto the surface.

Images